<?xml version="1.0" encoding="utf-8"?>
<!-- generator="FeedCreator 1.7.2-ppt (info@mypapit.net)" -->
<feed xmlns="http://www.w3.org/2005/Atom">
    <title>Reuters News Articles By Ben Hirschler</title>
    <subtitle>Find the latest breaking news from around the world on Reuters.com, including news articles on politics, technology, business, entertainment and more.</subtitle>
    <link rel="alternate" type="text/html" href="http://www.reuters.com/"/>
    <id>http://www.reuters.com/</id>
    <updated>2009-11-27T05:09:42+01:00</updated>
    <generator>FeedCreator 1.7.2-ppt (info@mypapit.net)</generator>
<link rel="self" type="application/atom+xml" href="http://blogs.reuters.com/wp-content/plugins/reuters-author-news-rss-feed/feed.php?author=Ben Hirschler" />
    <entry>
        <title>Blame game slows growth of personalized medicine</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/ousiv/idUSTRE5AP20920091126"/>
        <published>2009-11-26T12:50:32+01:00</published>
        <updated>2009-11-26T12:50:32+01:00</updated>
        <id>http://www.reuters.com/article/ousiv/idUSTRE5AP20920091126</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary>LONDON (Reuters) - Expectation has been building for a decade that an era of personalized medicine will transform the global drugs business, but the reality is a slow start and an angry blame game between scientists, marketers and regulators.</summary>
    </entry>
    <entry>
        <title>UK cost body again rejects Roche bowel cancer drug</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/swissMktRpt/idUSGEE5AM1DU20091124"/>
        <published>2009-11-24T00:01:18+01:00</published>
        <updated>2009-11-24T00:01:18+01:00</updated>
        <id>http://www.reuters.com/article/swissMktRpt/idUSGEE5AM1DU20091124</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> LONDON, Nov 24 (Reuters) - Britain's healthcare
cost-effectiveness watchdog has again rejected Roche's &amp;lt;ROG.VX&amp;gt;
drug Avastin as a treatment for bowel cancer, saying it is too
expensive.</summary>
    </entry>
    <entry>
        <title>UPDATE 1-Glaxo temporarily withdraws Avodart cancer filing</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/euRegulatoryNews/idUSGEE5AM1SM20091123"/>
        <published>2009-11-23T14:40:05+01:00</published>
        <updated>2009-11-23T14:40:05+01:00</updated>
        <id>http://www.reuters.com/article/euRegulatoryNews/idUSGEE5AM1SM20091123</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * Says needs to update data, unrelated to safety or efficacy</summary>
    </entry>
    <entry>
        <title>UPDATE 1-EU body backs single dose for 2 H1N1 flu vaccines</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/healthcareSector/idUSLK65377620091120"/>
        <published>2009-11-20T13:36:29+01:00</published>
        <updated>2009-11-20T13:36:29+01:00</updated>
        <id>http://www.reuters.com/article/healthcareSector/idUSLK65377620091120</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * EMEA says single dose of Glaxo, Novartis vaccines enough</summary>
    </entry>
    <entry>
        <title>UPDATE 3-U.S. panel rejects Xolair asthma drug for children</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/swissMktRpt/idUSN1812824820091118"/>
        <published>2009-11-18T23:21:13+01:00</published>
        <updated>2009-11-18T23:21:13+01:00</updated>
        <id>http://www.reuters.com/article/swissMktRpt/idUSN1812824820091118</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * FDA advisory panel votes 10-4 against approval of Xolair</summary>
    </entry>
    <entry>
        <title>UPDATE 3-U.S. panel rejects Xolair asthma drug for children</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/rbssPharmaceuticals%20-%20Diversified/idUSN1812824820091118"/>
        <published>2009-11-18T23:21:13+01:00</published>
        <updated>2009-11-18T23:21:13+01:00</updated>
        <id>http://www.reuters.com/article/rbssPharmaceuticals%20-%20Diversified/idUSN1812824820091118</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * FDA advisory panel votes 10-4 against approval of Xolair</summary>
    </entry>
    <entry>
        <title>UPDATE 3-U.S. panel rejects Xolair asthma drug for children</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/governmentFilingsNews/idUSN1812824820091118"/>
        <published>2009-11-18T23:21:13+01:00</published>
        <updated>2009-11-18T23:21:13+01:00</updated>
        <id>http://www.reuters.com/article/governmentFilingsNews/idUSN1812824820091118</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * FDA advisory panel votes 10-4 against approval of Xolair</summary>
    </entry>
    <entry>
        <title>FDA warns heartburn drugs interfere with Plavix</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/healthNews/idUSTRE5AG4ES20091117"/>
        <published>2009-11-17T18:04:56+01:00</published>
        <updated>2009-11-17T18:04:56+01:00</updated>
        <id>http://www.reuters.com/article/healthNews/idUSTRE5AG4ES20091117</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary>WASHINGTON (Reuters) - Common heartburn pills Prilosec and Nexium cut the blood-thinning effect of Sanofi-Aventis SA's and Bristol-Myers Squibb Co's heart drug Plavix, U.S. officials warned on Tuesday.</summary>
    </entry>
    <entry>
        <title>Icelandic gene pioneer Decode files for bankruptcy</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/healthNews/idUSTRE5AG52M20091117"/>
        <published>2009-11-17T20:01:28+01:00</published>
        <updated>2009-11-17T20:01:28+01:00</updated>
        <id>http://www.reuters.com/article/healthNews/idUSTRE5AG52M20091117</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary>WASHINGTON (Reuters) - Iceland's Decode Genetics Inc, a pioneer in genetic research, has filed for bankruptcy protection, weighed down by debts after 13 years of failing to make a profit.</summary>
    </entry>
    <entry>
        <title>UPDATE 3-Icelandic gene pioneer Decode files for bankruptcy</title>
        <link rel="alternate" type="text/html" href="http://www.reuters.com/article/euMergersNews/idUSBNG53045020091117"/>
        <published>2009-11-17T19:56:52+01:00</published>
        <updated>2009-11-17T19:56:52+01:00</updated>
        <id>http://www.reuters.com/article/euMergersNews/idUSBNG53045020091117</id>
        <author>
            <name>Ben Hirschler</name>
        </author>
        <summary> * Lists assets of $69.9 million, debt of $313.9 million</summary>
    </entry>
</feed>
